Description: BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.
Home Page: bioagelabs.com
1445A South 50th Street
Richmond,
CA
94804
United States
Phone:
510 806 1445
Officers
| Name | Title |
|---|---|
| Dr. Kristen Fortney Ph.D. | Co-Founder, CEO, President, Treasurer, Secretary & Director |
| Mr. Eric Morgen M.D. | Co-Founder, COO & Director |
| Dr. Paul D. Rubin M.D. | Chief Medical Officer & Executive VP of Research |
| Dr. Dov A. Goldstein M.B.A., M.D. | Chief Financial Officer |
| Mr. Ralph Scarborough | Vice President of Finance & Accounting |
| Mr. Rusty Montgomery Ph.D. | Senior Vice President of Research |
| Ms. Julie Gammelgard | Senior Vice President of People |
| Dr. Peng Leong M.B.A., Ph.D. | Chief Business Officer & Therapeutic Area Head of Brain Aging |
| Dr. Carrie-Lynn Langlais Furr | Senior Vice President of Regulatory Affairs |
| Mr. Justin Rebo | Senior Vice President of Translational Aging Biology |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2024-09-26 |
| Fiscal Year End: | December |
| Full Time Employees: | 56 |